Integral BioSystems LLC to display in Booth 933 at the ARVO Annual Meeting from April 29 to May 3, 2018, at the Hawaii Convention Center in Honolulu, Hawaii.
BEDFORD, MA, US, April 25, 2018 /EINPresswire.com/ — Integral BioSystems LLC, Boston area CRO specializing in ophthalmological pharmaceutical formulation development, will be in the spotlight as a participating exhibitor (Booth # 933) during the ARVO 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology from April 29, 2018 to May 3, 2018, to be held at the Hawaii Convention Center in Honolulu, Hawaii.
With almost 40 years of combined experience in all phases of tissue targeted, sustained release pharmaceutical formulation development, the firm’s CEO and President, Dr. Shikha P. Barman and Head of R&D, Kevin Ward will be available to discuss the specific requirements of interested attendees. In addition, Integral BioSystems scientists will be presenting three posters based on its internal drug development programs, based on the company’s issued patents on its platform technologies at the following times and locations:
Sunday, April 29, 2018: Sustained Release of Small Hydrophilic Peptides to the Ocular Surface via NanoM™
Shikha Barman, Yang Li, Laura Kaminski, Chunhong Li and Kevin Ward
Poster ID 238-C0049; 8:30 AM-10:15 AM
Sunday, April 29, 2018: Development of a Highly Bioavailable, Sustained Release Nanocore-based (OcuSurf™) Ophthalmic Formulation for the Treatment of Blepharitis
Kevin Ward, Koushik Barman, Chunhong Li, Yugang Chen, Yang Li and Kevin Ward
Poster ID 230-C0041: 8:30 AM-10:15 AM
Thursday, May 3, 2018: A Bioavailable, Sustained Release Nanocore (OcuSurf™) Brinzolamide Drug Product for Glaucoma Therapy
Koushik Barman, Chunhong Li, Yugang Chen, Yang Li, Kevin Ward and Shikha Barman
Poster ID: 5690-A0409; 8:30 AM-10:15 AM
About the Symposium
The ARVO 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology will cover subjects like Medicine, Eyesight, Vision, Ophthalmology, and Eye Health. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. It is anticipated that nearly 11,000 people will participate in this Meeting.
About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.
The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.
For those seeking to develop a formulation for a new drug substance, a 505b2 product or a generic drug product, Dr. Barman will be available to answer questions about the suitability of Integral’s recently patented drug delivery platform technologies, NanoM™ and OcuSurf™, for any desired application.
Integral BioSystems, LLC
email us here
Source: EIN Presswire